{"title":"Sars-COV-2感染和COVID疫苗接种后单肉毒杆菌毒素和单肉毒杆菌毒素缺乏治疗效果和持续时间。","authors":"Ali McCoy Stengel, J Cole Stengel","doi":"10.1097/PSN.0000000000000610","DOIUrl":null,"url":null,"abstract":"<p><p>This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.</p>","PeriodicalId":74460,"journal":{"name":"Plastic and aesthetic nursing","volume":"45 3","pages":"150-156"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination.\",\"authors\":\"Ali McCoy Stengel, J Cole Stengel\",\"doi\":\"10.1097/PSN.0000000000000610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.</p>\",\"PeriodicalId\":74460,\"journal\":{\"name\":\"Plastic and aesthetic nursing\",\"volume\":\"45 3\",\"pages\":\"150-156\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plastic and aesthetic nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PSN.0000000000000610\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plastic and aesthetic nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PSN.0000000000000610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Lack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination.
This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.